Latest

SeminarNeuroscienceRecording

Memory Decoding Journal Club: Functional connectomics reveals general wiring rule in mouse visual cortex

Ariel Zeleznikow-Johnston
Monash University
Oct 21, 2025

Functional connectomics reveals general wiring rule in mouse visual cortex

SeminarNeuroscienceRecording

Memory Decoding Journal Club: A combinatorial neural code for long-term motor memory

Ariel Zeleznikow-Johnston
Monash University
Sep 9, 2025

A combinatorial neural code for long-term motor memory

SeminarNeuroscienceRecording

Memory Decoding Journal Club: Systems consolidation reorganizes hippocampal engram circuitry

Ariel Zeleznikow-Johnston
Monash University
Jul 1, 2025

Systems consolidation reorganizes hippocampal engram circuitry

SeminarNeuroscienceRecording

Motor learning selectively strengthens cortical and striatal synapses of motor engram neurons

Ariel Zeleznikow-Johnston
Monash University
May 6, 2025

Join Us for the Memory Decoding Journal Club! A collaboration of the Carboncopies Foundation and BPF Aspirational Neuroscience. This time, we’re diving into a groundbreaking paper: "Motor learning selectively strengthens cortical and striatal synapses of motor engram neurons

SeminarNeuroscience

Development of a small molecule to promote neuroprotection and repair in progressive multiple sclerosis

Petratos Steven
Department of Neuroscience / School of Translational Medicine Monash University, Australia
Jul 8, 2024
SeminarNeuroscience

Consciousness in the cradle: on the emergence of infant experience

Tim Bayne & Joel Frohlich
Monash University & University of Tübingen
Nov 30, 2023

Although each of us was once a baby, infant consciousness remains mysterious and there is no received view about when, and in what form, consciousness first emerges. Some theorists defend a ‘late-onset’ view, suggesting that consciousness requires cognitive capacities which are unlikely to be in place before the child’s first birthday at the very earliest. Other theorists defend an ‘early-onset’ account, suggesting that consciousness is likely to be in place at birth (or shortly after) and may even arise during the third trimester. Progress in this field has been difficult, not just because of the challenges associated with procuring the relevant behavioral and neural data, but also because of uncertainty about how best to study consciousness in the absence of the capacity for verbal report or intentional behavior. This review examines both the empirical and methodological progress in this field, arguing that recent research points in favor of early-onset accounts of the emergence of consciousness.

SeminarNeuroscience

Integrating theory-guided and data-driven approaches for measuring consciousness

Nao Tsuchiya
Monash Institute of Cognitive and Clinical Neurosciences, Monash University
Aug 31, 2022

Clinical assessment of consciousness is a significant issue, with recent research suggesting some brain-damaged patients who are assessed as unconscious are in fact conscious. Misdiagnosis of consciousness can also be detrimental when it comes to general anaesthesia, causing numerous psychological problems, including post-traumatic stress disorder. Avoiding awareness with overdose of anaesthetics, however, can also lead to cognitive impairment. Currently available objective assessment of consciousness is limited in accuracy or requires expensive equipment with major barriers to translation. In this talk, we will outline our recent theory-guided and data-driven approaches to develop new, optimized consciousness measures that will be robustly evaluated on an unprecedented breadth of high-quality neural data, recorded from the fly model system. We will overcome the subjective-choice problem in data-driven and theory-guided approaches with a comprehensive data analytic framework, which has never been applied to consciousness detection, integrating previously disconnected streams of research in consciousness detection to accelerate the translation of objective consciousness measures into clinical settings.

SeminarNeuroscienceRecording

Linking GWAS to pharmacological treatments for psychiatric disorders

Aurina Arnatkeviciute
Monash University
Aug 19, 2022

Genome-wide association studies (GWAS) have identified multiple disease-associated genetic variations across different psychiatric disorders raising the question of how these genetic variants relate to the corresponding pharmacological treatments. In this talk, I will outline our work investigating whether functional information from a range of open bioinformatics datasets such as protein interaction network (PPI), brain eQTL, and gene expression pattern across the brain can uncover the relationship between GWAS-identified genetic variation and the genes targeted by current drugs for psychiatric disorders. Focusing on four psychiatric disorders---ADHD, bipolar disorder, schizophrenia, and major depressive disorder---we assess relationships between the gene targets of drug treatments and GWAS hits and show that while incorporating information derived from functional bioinformatics data, such as the PPI network and spatial gene expression, can reveal links for bipolar disorder, the overall correspondence between treatment targets and GWAS-implicated genes in psychiatric disorders rarely exceeds null expectations. This relatively low degree of correspondence across modalities suggests that the genetic mechanisms driving the risk for psychiatric disorders may be distinct from the pathophysiological mechanisms used for targeting symptom manifestations through pharmacological treatments and that novel approaches for understanding and treating psychiatric disorders may be required.

SeminarNeuroscience

Learning with less labels for medical image segmentation

Mehrtash Harandi
Monash University
Aug 3, 2022

Accurate segmentation of medical images is a key step in developing Computer-Aided Diagnosis (CAD) and automating various clinical tasks such as image-guided interventions. The success of state-of-the-art methods for medical image segmentation is heavily reliant upon the availability of a sizable amount of labelled data. If the required quantity of labelled data for learning cannot be reached, the technology turns out to be fragile. The principle of consensus tells us that as humans, when we are uncertain how to act in a situation, we tend to look to others to determine how to respond. In this webinar, Dr Mehrtash Harandi will show how to model the principle of consensus to learn to segment medical data with limited labelled data. In doing so, we design multiple segmentation models that collaborate with each other to learn from labelled and unlabelled data collectively.

SeminarNeuroscience

The glymphatic system in motor neurone disease

David Wright
Monash University
Jul 6, 2022

Neurodegenerative diseases are chronic and inexorable conditions characterised by the presence of insoluble aggregates of abnormally ubiquinated and phosphorylated proteins. Recent evidence also suggests that protein misfolding can propagate throughout the body in a prion-like fashion via the interstitial or cerebrospinal fluids (CSF). As protein aggregation occurs well before the onset of brain damage and symptoms, new biomarkers sensitive to early pathology, together with therapeutic strategies that include eliminating seed proteins and blocking cell-to-cell spread, are of vital importance. The glymphatic system, which facilitates the continuous exchange of CSF and interstitial fluid to clear the brain of waste, presents as a potential biomarker of disease severity, therapeutic target, and drug delivery system. In this webinar, Associate Professor David Wright from the Department of Neuroscience, Monash University, will outline recent advances in using MRI to investigate the glymphatic system. He will also present some of his lab’s recent work investigating glymphatic clearance in preclinical models of motor neurone disease. Associate Professor David Wright is an NHMRC Emerging Leadership Fellow and the Director of Preclinical Imaging in the Department of Neuroscience, Monash University and the Alfred Research Alliance, Alfred Health. His research encompasses the development, application and analysis of advanced magnetic resonance imaging techniques for the study of disease, with a particular emphasis on neurodegenerative disorders. Although less than three years post PhD, he has published over 60 peer-reviewed journal articles in leading neuroscience journals such as Nature Medicine, Brain, and Cerebral Cortex.

SeminarNeuroscience

PET imaging in brain diseases

Bianca Jupp and Lucy Vivash
Monash University
Jun 8, 2022

Talk 1. PET based biomarkers of treatment efficacy in temporal lobe epilepsy A critical aspect of drug development involves identifying robust biomarkers of treatment response for use as surrogate endpoints in clinical trials. However, these biomarkers also have the capacity to inform mechanisms of disease pathogenesis and therapeutic efficacy. In this webinar, Dr Bianca Jupp will report on a series of studies using the GABAA PET ligand, [18F]-Flumazenil, to establish biomarkers of treatment response to a novel therapeutic for temporal lobe epilepsy, identifying affinity at this receptor as a key predictor of treatment outcome. Dr Bianca Jupp is a Research Fellow in the Department of Neuroscience, Monash University and Lead PET/CT Scientist at the Alfred Research Alliance–Monash Biomedical Imaging facility. Her research focuses on neuroimaging and its capacity to inform the neurobiology underlying neurological and neuropsychiatric disorders. Talk 2. The development of a PET radiotracer for reparative microglia Imaging of neuroinflammation is currently hindered by the technical limitations associated with TSPO imaging. In this webinar, Dr Lucy Vivash will discuss the development of PET radiotracers that specifically image reparative microglia through targeting the receptor kinase MerTK. This includes medicinal chemistry design and testing, radiochemistry, and in vitro and in vivo testing of lead tracers. Dr Lucy Vivash is a Research Fellow in the Department of Neuroscience, Monash University. Her research focuses on the preclinical development and clinical translation of novel PET radiotracers for the imaging of neurodegenerative diseases.

SeminarNeuroscience

Growing a world-class precision medicine industry

Prof Gary Egan and Dr Maggie Aulsebrook
Monash Biomedical Imaging
May 25, 2022

Monash Biomedical Imaging is part of the new $71.2 million Australian Precision Medicine Enterprise (APME) facility, which will deliver large-scale development and manufacturing of precision medicines and theranostic radiopharmaceuticals for industry and research. A key feature of the APME project is a high-energy cyclotron with multiple production clean rooms, which will be located on the Monash Biomedical Imaging (MBI) site in Clayton. This strategic co-location will facilitate radiochemistry, PET and SPECT research and clinical use of theranostic (therapeutic and diagnostic) radioisotopes produced on-site. In this webinar, MBI’s Professor Gary Egan and Dr Maggie Aulsebrook will explain how the APME will secure Australia’s supply of critical radiopharmaceuticals, build a globally competitive Australian manufacturing hub, and train scientists and engineers for the Australian workforce. They will cover the APME’s state-of-the-art 30 MeV and 18-24 MeV cyclotrons and radiochemistry facilities, as well as the services that will be accessible to students, scientists, clinical researchers, and pharmaceutical companies in Australia and around the world. The APME is a collaboration between Monash University, Global Medical Solutions Australia, and Telix Pharmaceuticals. Professor Gary Egan is Director of Monash Biomedical Imaging, Director of the ARC Centre of Excellence for Integrative Brain Function and a Distinguished Professor at the Turner Institute for Brain and Mental Health, Monash University. He is also lead investigator of the Victorian Biomedical Imaging Capability, and Deputy Director of the Australian National Imaging Facility. Dr Maggie Aulsebrook obtained her PhD in Chemistry at Monash University and specialises in the development and clinical translation of radiopharmaceuticals. She has led the development of several investigational radiopharmaceuticals for first-in-human application. Maggie leads the Radiochemistry Platform at Monash Biomedical Imaging.

SeminarNeuroscience

The neuroscience of lifestyle interventions for mental health: the BrainPark approach

Rebecca Segrave and Chao Suo
Monash University
Mar 16, 2022

Our everyday behaviours, such as physical activity, sleep, diet, meditation, and social connections, have a potent impact on our mental health and the health of our brain. BrainPark is working to harness this power by developing lifestyle-based interventions for mental health and investigating how they do and don’t change the brain, and for whom they are most effective. In this webinar, Dr Rebecca Segrave and Dr Chao Suo will discuss BrainPark’s approach to developing lifestyle-based interventions to help people get better control of compulsive behaviours, and the multi-modality neuroimaging approaches they take to investigating outcomes. The webinar will explore two current BrainPark trials: 1. Conquering Compulsions - investigating the capacity of physical exercise and meditation to alter reward processing and help people get better control of a wide range of unhelpful habits, from drinking to eating to cleaning. 2. The Brain Exercise Addiction Trial (BEAT) - an NHMRC funded investigation into the capacity of physical exercise to reverse the brain harms caused by long-term heavy cannabis use. Dr Rebecca Segrave is Deputy Director and Head of Interventions Research at BrainPark, the David Winston Turner Senior Research Fellow within the Turner Institute for Brain and Mental Health, and an AHRPA registered Clinical Neuropsychologist. Dr Chao Suo is Head of Technology and Neuroimaging at BrainPark and a Research Fellow within the Turner Institute for Brain and Mental Health.

SeminarNeuroscience

Free will beyond spontaneous volition: Conscious control processes of inhibition and attention in self-control and free will

Timothy Bayne/Polaris Koi/Jake Gavenas
Monash University/University of Turku/Chapman University
Feb 15, 2022

Polaris Koi (Philosophy) and Jake Gavenas (Neuroscience) begin the seminar by arguing that agentive control is the key requirement for free will, drawing on folk-philosophy findings to support this claim (Gavenas et al., in prep). They explore how two executive control processes that functionally involve consciousness—inhibition and top-down control of attention—connect self-control and free will.

SeminarNeuroscienceRecording

Inferring informational structures in neural recordings of drosophila with epsilon-machines

Roberto Muñoz
Monash University
Dec 10, 2021

Measuring the degree of consciousness an organism possesses has remained a longstanding challenge in Neuroscience. In part, this is due to the difficulty of finding the appropriate mathematical tools for describing such a subjective phenomenon. Current methods relate the level of consciousness to the complexity of neural activity, i.e., using the information contained in a stream of recorded signals they can tell whether the subject might be awake, asleep, or anaesthetised. Usually, the signals stemming from a complex system are correlated in time; the behaviour of the future depends on the patterns in the neural activity of the past. However these past-future relationships remain either hidden to, or not taken into account in the current measures of consciousness. These past-future correlations are likely to contain more information and thus can reveal a richer understanding about the behaviour of complex systems like a brain. Our work employs the "epsilon-machines” framework to account for the time correlations in neural recordings. In a nutshell, epsilon-machines reveal how much of the past neural activity is needed in order to accurately predict how the activity in the future will behave, and this is summarised in a single number called "statistical complexity". If a lot of past neural activity is required to predict the future behaviour, then can we say that the brain was more “awake" at the time of recording? Furthermore, if we read the recordings in reverse, does the difference between forward and reverse-time statistical complexity allow us to quantify the level of time asymmetry in the brain? Neuroscience predicts that there should be a degree of time asymmetry in the brain. However, this has never been measured. To test this, we used neural recordings measured from the brains of fruit flies and inferred the epsilon-machines. We found that the nature of the past and future correlations of neural activity in the brain, drastically changes depending on whether the fly was awake or anaesthetised. Not only does our study find that wakeful and anaesthetised fly brains are distinguished by how statistically complex they are, but that the amount of correlations in wakeful fly brains was much more sensitive to whether the neural recordings were read forward vs. backwards in time, compared to anaesthetised brains. In other words, wakeful fly brains were more complex, and time asymmetric than anaesthetised ones.

SeminarNeuroscience

Monash Biomedical Imaging highlights from 2021 and looking ahead to 2022

Gary Egan
Monash Biomedical Imaging
Dec 9, 2021

Despite the challenges COVID-19 has continued to present, Monash Biomedical Imaging (MBI) has had another outstanding year in terms of publications and scientific output. In this webinar, Professor Gary Egan, Director of MBI, will present an overview of MBI’s achievements during 2021 and outline the biomedical imaging research programs and partnerships in 2022. His presentation will cover: • MBI operational and research achievements during 2021 • Biomedical imaging technology developments and research outcomes during 2021 • Linked laboratories and research teams at MBI • Progress on the development of a cyclotron and precision radiopharmaceutical facility at Clayton • Emerging research opportunities at the Monash Heart Hospital in cardiology and cardiovascular disease. Professor Gary Egan is Director of Monash Biomedical Imaging, Director of the ARC Centre of Excellence for Integrative Brain Function and a Distinguished Professor at the Turner Institute for Brain and Mental Health, Monash University. He is also lead investigator of the Victorian Biomedical Imaging Capability, and Deputy Director of the Australian National Imaging Facility. His substantive body of published work has made a significant impact on the neuroimaging and neuroscience fields. He has sustained success in obtaining significant grants to support his own research and the development of facilities to advance biomedical imaging.

SeminarNeuroscienceRecording

The Unfolding Argument: theoretical and methodological implications

Niccolo Negro
Monash University
Dec 2, 2021

In the first part of this talk, I will briefly present the unfolding argument by Doerig et al. (2019) and the various replies in the philosophical and neuroscientific literature. In the second part of the talk, I will explore the ramifications that this debate has for the science of consciousness and its philosophy, with particular focus on these questions: (i) which type of explanation should a theory of consciousness provide? (ii) what is the evidential basis for theories of consciousness?

SeminarNeuroscienceRecording

Generative models of brain function: Inference, networks, and mechanisms

Adeel Razi
Monash University
Nov 26, 2021

This talk will focus on the generative modelling of resting state time series or endogenous neuronal activity. I will survey developments in modelling distributed neuronal fluctuations – spectral dynamic causal modelling (DCM) for functional MRI – and how this modelling rests upon functional connectivity. The dynamics of brain connectivity has recently attracted a lot of attention among brain mappers. I will also show a novel method to identify dynamic effective connectivity using spectral DCM. Further, I will summarise the development of the next generation of DCMs towards large-scale, whole-brain schemes which are computationally inexpensive, to the other extreme of the development using more sophisticated and biophysically detailed generative models based on the canonical microcircuits.

SeminarNeuroscience

Neural mechanisms of altered states of consciousness under psychedelics

Adeel Razi and Devon Stoliker
Monash Biomedical Imaging
Nov 11, 2021

Interest in psychedelic compounds is growing due to their remarkable potential for understanding altered neural states and their breakthrough status to treat various psychiatric disorders. However, there are major knowledge gaps regarding how psychedelics affect the brain. The Computational Neuroscience Laboratory at the Turner Institute for Brain and Mental Health, Monash University, uses multimodal neuroimaging to test hypotheses of the brain’s functional reorganisation under psychedelics, informed by the accounts of hierarchical predictive processing, using dynamic causal modelling (DCM). DCM is a generative modelling technique which allows to infer the directed connectivity among brain regions using functional brain imaging measurements. In this webinar, Associate Professor Adeel Razi and PhD candidate Devon Stoliker will showcase a series of previous and new findings of how changes to synaptic mechanisms, under the control of serotonin receptors, across the brain hierarchy influence sensory and associative brain connectivity. Understanding these neural mechanisms of subjective and therapeutic effects of psychedelics is critical for rational development of novel treatments and for the design and success of future clinical trials. Associate Professor Adeel Razi is a NHMRC Investigator Fellow and CIFAR Azrieli Global Scholar at the Turner Institute of Brain and Mental Health, Monash University. He performs cross-disciplinary research combining engineering, physics, and machine-learning. Devon Stoliker is a PhD candidate at the Turner Institute for Brain and Mental Health, Monash University. His interest in consciousness and psychiatry has led him to investigate the neural mechanisms of classic psychedelic effects in the brain.

SeminarNeuroscience

Developing metal-based radiopharmaceuticals for imaging and therapy

Brett Paterson and Cormac Kelderman
Monash Biomedical Imaging
Jul 8, 2021

Personalised medicine will be greatly enhanced with the introduction of new radiopharmaceuticals for the diagnosis and treatment of various cancers, as well as cardiovascular disease and brain disorders. The unprecedented interest in developing theranostic radiopharmaceuticals is mainly due to the recent clinical successes of radiometal-based products including: • 177LuDOTA-TATE (trade name Lutathera, FDA approved in 2018), a peptide-based tracer that is used for treating metastatic neuroendocrine tumours • Ga 68 PSMA-11 (FDA approved in 2020), a positron emission tomography agent for imaging prostate-specific membrane antigen positive lesions in men with prostate cancer. In this webinar, Dr Brett Paterson and PhD candidate Mr Cormac Kelderman will present their research on developing the chemistry and radiochemistry to produce new radiometal-based imaging and therapy agents. They will discuss the synthesis of new molecules, the optimisation of the radiochemistry, and results from preclinical evaluations. Dr Brett Paterson is a National Imaging Facility Fellow at Monash Biomedical Imaging and academic group leader in the School of Chemistry, Monash University. His research focuses on the development of radiochemistry and new radiopharmaceuticals. Cormac Kelderman is a PhD candidate under the supervision of Dr Brett Paterson in the School of Chemistry, Monash University. His research focuses on developing new bis(thiosemicarbazone) chelators for technetium-99m SPECT imaging.

SeminarNeuroscience

Fragility of the human connectome across the lifespan

Leonardo Gollo and James Pang
Monash Biomedical Imaging
May 13, 2021

The human brain network architecture can reveal crucial aspects of brain function and dysfunction. The topology of this network (known as the connectome) is shaped by a trade-off between wiring cost and network efficiency, and it has highly connected hub regions playing a prominent role in many brain disorders. By studying a landscape of plausible brain networks that preserve the wiring cost, fragile and resilient hubs can be identified. In this webinar, Dr Leonardo Gollo and Dr James Pang from Monash University will discuss this approach across the lifespan and some of its implications for neurodevelopmental and neurodegenerative diseases. Dr Leonardo Gollo is a Senior Research Fellow at the Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University. He holds an ARC Future Fellowship and his research interests include brain modelling, systems neuroscience, and connectomics. Dr James Pang is a Research Fellow at the Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University. His research interests are on combining neuroimaging and biophysical modelling to better understand the mechanisms of brain function in health and disease.

SeminarNeuroscienceRecording

How to Construct A Consciousness Meter

Timothy Bayne
Monash University
Nov 20, 2020

One of the central challenges facing the science of consciousness is that of identifying ways of measuring consciousness. Can we go beyond our pre-theoretical ways of detecting consciousness and develop independently validated measures of consciousness. Some theorists think not, arguing that we cannot go beyond the everyday markers of consciousness with which we begin. Others are more optimistic, and hold that we will be able to develop independent measures of consciousness, or "consciousness meters". This talk discusses various ways in which one might attempt to validate a consciousness meter, arguing that the most promising approach involves treating consciousness as a natural kind.

SeminarNeuroscience

Using marmosets for the study of the visual cortex: unique opportunities, and some pitfalls

Marcello Rosa
Monash University
Nov 17, 2020

Marmosets (Callithrix jacchus) are small South American monkeys which are being increasingly becoming adopted as animal models in neuroscience. Knowledge about the marmoset visual system has developed rapidly over the last decade. But what are the comparative advantages, and disadvantages involved in adopting this emerging model, as opposed to the more traditionally used macaque monkey? In this talk I will present case studies where the simpler brain morphology and short developmental cycle of the marmoset have been key factors in facilitating discoveries about the anatomy and physiology of the visual system. Although no single species provides the “ideal” animal model for invasive studies of the neural bases of visual processing, I argue that the development of robust methodologies for the study of the marmoset brain provides exciting opportunities to address long-standing problems in neuroscience.

SeminarNeuroscienceRecording

Biomarkers for Addiction Treatment Development: fMRI Drug Cue Reactivity as an Example

Hugh Garavan, Antonio Verdejo-García, Anna Zilverstand, Hamed Ekhtiari
University of Vermont, Monash University, University of Minnesota, Laureate Institute for Brain Research
Oct 29, 2020

This webinar is mainly focused on “Biomarkers for Addiction Treatment Development: fMRI Drug Cue Reactivity as an Example”. Biomarkers and Biotypes of Drug Addiction: funding opportunities at NIDA, Tanya Ramey (NIDA, US) Neuroimaging-based Biomarker Development for Clinical Trials, Owen Carmicheal (Pennington Biomedical Research Center, USA) ENIGMA-Addiction Cue Reactivity Initiative (ACRI) and Checklist, Hamed Ekhtiari (Laureate Institute for Brain Research, USA) ENIGMA-ACRI Checklist: Participant Characteristics, General fMRI Information, General Task Information, Cue Information, Task-related Assessments, Pre-Post Scanning Consideration (James Prisciandaro, Medical University of South Carolina, USA; Marc Kaufman, McLean Hospital/Harvard Medical School, USA; Anna Zilverstand, University of Minnesota; Torsten Wüstenberg, Charité Medical University Berlin, Germany; Falk Kiefer, University of Heidelberg, Germany; Amy Janes, Harvard Medical School, USA) How to Add fMRI Drug Cue Reactivity to the ENIGMA Consortium: Road Ahead, Hugh Garavan, University of Vermont)

SeminarNeuroscience

Delineating Reward/Avoidance Decision Process in the Impulsive-compulsive Spectrum Disorders through a Probabilistic Reversal Learning Task

Xiaoliu Zhang
Monash University
Jul 19, 2020

Impulsivity and compulsivity are behavioural traits that underlie many aspects of decision-making and form the characteristic symptoms of Obsessive Compulsive Disorder (OCD) and Gambling Disorder (GD). The neural underpinnings of aspects of reward and avoidance learning under the expression of these traits and symptoms are only partially understood. " "The present study combined behavioural modelling and neuroimaging technique to examine brain activity associated with critical phases of reward and loss processing in OCD and GD. " "Forty-two healthy controls (HC), forty OCD and twenty-three GD participants were recruited in our study to complete a two-session reinforcement learning (RL) task featuring a “probability switch (PS)” with imaging scanning. Finally, 39 HC (20F/19M, 34 yrs +/- 9.47), 28 OCD (14F/14M, 32.11 yrs ±9.53) and 16 GD (4F/12M, 35.53yrs ± 12.20) were included with both behavioural and imaging data available. The functional imaging was conducted by using 3.0-T SIEMENS MAGNETOM Skyra syngo MR D13C at Monash Biomedical Imaging. Each volume compromised 34 coronal slices of 3 mm thickness with 2000 ms TR and 30 ms TE. A total of 479 volumes were acquired for each participant in each session in an interleaved-ascending manner. " " The standard Q-learning model was fitted to the observed behavioural data and the Bayesian model was used for the parameter estimation. Imaging analysis was conducted using SPM12 (Welcome Department of Imaging Neuroscience, London, United Kingdom) in the Matlab (R2015b) environment. The pre-processing commenced with the slice timing, realignment, normalization to MNI space according to T1-weighted image and smoothing with a 8 mm Gaussian kernel. " " The frontostriatal brain circuit including the putamen and medial orbitofrontal (mOFC) were significantly more active in response to receiving reward and avoiding punishment compared to receiving an aversive outcome and missing reward at 0.001 with FWE correction at cluster level; While the right insula showed greater activation in response to missing rewards and receiving punishment. Compared to healthy participants, GD patients showed significantly lower activation in the left superior frontal and posterior cingulum at 0.001 for the gain omission. " " The reward prediction error (PE) signal was found positively correlated with the activation at several clusters expanding across cortical and subcortical region including the striatum, cingulate, bilateral insula, thalamus and superior frontal at 0.001 with FWE correction at cluster level. The GD patients showed a trend of decreased reward PE response in the right precentral extending to left posterior cingulate compared to controls at 0.05 with FWE correction. " " The aversive PE signal was negatively correlated with brain activity in regions including bilateral thalamus, hippocampus, insula and striatum at 0.001 with FWE correction. Compared with the control group, GD group showed an increased aversive PE activation in the cluster encompassing right thalamus and right hippocampus, and also the right middle frontal extending to the right anterior cingulum at 0.005 with FWE correction. " " Through the reversal learning task, the study provided a further support of the dissociable brain circuits for distinct phases of reward and avoidance learning. Also, the OCD and GD is characterised by aberrant patterns of reward and avoidance processing.

Monash University coverage

27 items

Seminar27
Domain spotlight

Explore how Monash University research is advancing inside Neuro.

Visit domain